Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
FDI Summit Costa Rica: First edition of the event attracts new investors to the…
The FDI Summit is focused on the country's strategic sectors such as agribusiness, light and advanced manufacturing, life sciences, corporate services, digital technologies, semiconductors and tourism infrastructure. This diversification of sectors seeks to guarantee investment opportunities in all regions of the country. The FDI Summit is focused on the country's strategic sectors such as agribusiness, light and advanced manufacturing, life sciences, corporate services, digital technologies,...
PR Newswire
06/05/2024
Ipsen - Monthly information relative to the total number of voting rights and…
Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)30 April 202483,814,526Gross...
Nasdaq GlobeNewswire
06/05/2024
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to…
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMDLeuven, BELGIUM – May 6, 2024 – 6:00 PM CET, Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress in its preclinical program targeting Geographic Atrophy (GA), a severe and underserved form of Age-Related Macular Degeneration (AMD).This recently launched program has reached the first step with the identification of 50...
Nasdaq GlobeNewswire
06/05/2024
Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024
Press ReleaseNicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary General Meetings May 6, 2024 – release at 17h45 CETSophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, announced that the Ordinary and Extraordinary General Meetings were held today, on second convening...
Nasdaq GlobeNewswire
06/05/2024
Injectable Drug Delivery Market Worth $1139.4 billion | MarketsandMarkets™
Emerging economies are seeing rapid urbanization, improved healthcare infrastructure, and more healthcare spending, resulting in greater access to injectable drugs. As a result, pharmaceutical companies are focusing on extending their presence in these markets to drive market growth. Emerging economies are seeing rapid urbanization, improved healthcare infrastructure, and more healthcare spending, resulting in greater access to injectable drugs. As a result, pharmaceutical companies are...
PR Newswire
06/05/2024
Remote Patient Monitoring Market to Be Worth $116.84 Billion by 2031 - Exclusive…
Remote patient monitoring involves the use of connected medical devices to measure and monitor patient health data and transmit it to the healthcare provider. It also involves the use of software platforms to transmit the data to healthcare providers, where they can analyze the information and generate actionable insights. Healthcare professionals can intervene in disease management as necessary, either in person or virtually. Remote patient monitoring involves the use of connected medical...
PR Newswire
06/05/2024
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from April 29, 2024 to May 3, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
06/05/2024
JOY GROUP Ranks 70th in the WWD Beauty Inc Top 100, Moving Up the Ranking by 16…
As a respected publication known as the "Bible of Fashion", WWD holds considerable influence within the fashion world. The Top 100 Beauty Companies List, an annual ranking by WWD Beauty Inc of the world's largest beauty companies by sales, is a highly respected authority on the global beauty sector. As a respected publication known as the "Bible of Fashion", WWD holds considerable influence within the fashion world. The Top 100 Beauty Companies List, an annual ranking by WWD…
PR Newswire
06/05/2024
Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research…
The 50,000-square-foot facility, expected to be completed in 2025 and bring 170+ jobs to the Raleigh-Durham area, will serve as Solvias' North American hub for large molecule analytical services. It will offer critical cell-based potency assays, advanced Next-Gen Sequencing (NGS) capabilities, and related testing services supporting multiple biologic modalities. From the outset, the new testing center will support characterization and release testing of CGT and other advanced therapies…
PR Newswire
06/05/2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop…
"Seralutinib is a potential paradigm shifting therapy in PAH and PH-ILD, and we could not be more excited to partner with Gossamer to develop and bring this therapy to patients world-wide," said Giuseppe Accogli, CEO of Chiesi Group. "Gossamer shares Chiesi's commitment in using innovation to promote the health and well-being of people around the world and we are proud to add this collaboration as a key pillar to our next phase of growth." " Seralutinib is a potential…
PR Newswire
06/05/2024
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials ofAmpligen®(rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized...
Nasdaq GlobeNewswire
06/05/2024
INHEART RAISES $11M TO ACCELERATE DEVELOPMENT & DEPLOYMENT OF NOVEL THERAPEUTIC…
The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In addition, inHEART received funds from a successful crowdequity campaign on Tudigo and from the UK impact fund Astorg Foundation. The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In...
PR Newswire
06/05/2024
Calyx Medical Imaging Supports Groundbreaking Melanoma Treatment Approval
"The work that Iovance is doing is extremely important, not only to melanoma patients and their loved ones but also to the broader oncology research community," said David Herron, CEO of Calyx Medical Imaging. "We are honored to have played a role in this important development program and look forward to continuing our collaboration with the Iovance team." "The work that Iovance is doing is extremely important, not only to melanoma patients and their loved ones but also…
PR Newswire
06/05/2024
Endo Launches Enhanced TruDelivery® Ready-to-Use Product Line and Platform
The U.S. Food and Drug Administration (FDA) encourages the manufacture of products specifically designed to minimize medication errors. Even under the best circumstances, extra steps in product preparation, including mixing, compounding, or transfer to another container, may introduce the risk of error. The U.S. Food and Drug Administration (FDA)encouragesthe manufacture of products specifically designed to minimize medication errors. Even under the best circumstances, extra steps in...
PR Newswire
06/05/2024
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares…
Jefferies, Guggenheim Securities and Cantor are acting as joint book-running managers for the offering.A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective on March 14, 2024. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to...
Nasdaq GlobeNewswire
06/05/2024
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soonPresented clinical data at the American Association for Cancer Research (“AACR”) Annual Meeting for individualized and off-the-shelf mRNA-based cancer...
Nasdaq GlobeNewswire
06/05/2024
Navamedic ASA: Broad launch for Eroxon® in Sweden today
"Eroxon® is a fast, safe and easily available product developed to help men improve not only their sexual health but also their quality of life. We hope for a similar response in Sweden as in the UK and Norway. Over time, we see greater growth potential in Sweden because Eroxon® will be the only non-prescription treatment for erectile dysfunction in the market," says Jack Spira, Medical Director at Navamedic. "Eroxon® is a fast, safe and easily available product developed to help…
PR Newswire
06/05/2024
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides…
ZYNLONTA ®(loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased16%)1compared to 1Q 2023 Successfully completed LOTIS-7 dose escalation and initiated expansion in 2L+ DLBCLInitial MZL IIT Phase 2 data from 15 patients showed 13 patients with CR and 1 patient with PR; encouraging data compared to current treatments in area with high unmet medical needResearch event featured...
Nasdaq GlobeNewswire
06/05/2024
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2…
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All patients achieving responses maintained them at the time of data cutoffZYNLONTA was generally well-tolerated and safety was consistent with known profileData were presented at Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Scientific Workshop LAUSANNE, Switzerland, May...
Nasdaq GlobeNewswire
06/05/2024
Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to…
Brains Bio's Animal Health Division is empowered by the unique properties of its THC-free CBD API, which boasts an ultra-low detection limit of 0.000006%. This EU-GMP Certified API is pivotal in clinical and preclinical studies, including a Phase III Clinical Trial, highlighting its potential for therapeutic applications in veterinary medicine.The CBD API is supported by rigorous regulatory credentials, including ICH-Q7 compliance, an actively maintained EU Active Substance Master File...
Nasdaq GlobeNewswire
06/05/2024
Orion Corporation: Managers' transactions – Hilpi Rautelin
ORION CORPORATIONMANAGERS' TRANSACTIONS6 MAY 2024 at 12.00 EEST Orion Corporation: Managers' transactions – Hilpi Rautelin Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
06/05/2024
Boehringer Ingelheim shares positive results from the first study worldwide in…
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy. 1 DMI is a common, irreversible complication of diabetic retinopathy (DR) that...
Nasdaq GlobeNewswire
06/05/2024
Orion Corporation: Managers' transactions – Ari Lehtoranta
ORION CORPORATIONMANAGERS' TRANSACTIONS6 MAY 2024 at 12.00 EEST Orion Corporation: Managers' transactions – Ari Lehtoranta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
06/05/2024
Orion Corporation: Managers' transactions – Karen Lykke Sørensen
ORION CORPORATIONMANAGERS' TRANSACTIONS6 MAY 2024 at 12.00 EEST Orion Corporation: Managers' transactions – Karen Lykke Sørensen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
06/05/2024
Altri Comunicati